Download Files:
Products Details
Product Description
– Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects[1][2].
Web ID
– HY-103712
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C22H30N6O
Citations
– Int J Mol Sci. 2022 Feb 24;23(5):2493.|J Cancer Res Clin Oncol. 2022 Nov 18.|Cell Death Dis. 2019 Aug 9;10(8):602.|Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12986-12995.
References
– [1]Hazel P, et al. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. ChemMedChem. 2017 Mar 7;12(5):372-380.|[2]Patel H, et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Mol Cancer Ther. 2018 Jun;17(6):1156-1166.
CAS Number
– 1805833-75-3
Molecular Weight
– 394.51
SMILES
– O[C@H]1CNCC[C@@H]1CNC2=NC3=C(C(C)C)C=NN3C(NCC4=CC=CC=C4)=C2
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;CDK
Isoform
– CDK1;CDK2;CDK4;CDK5;CDK6;CDK7;CDK9
Pathway
– Apoptosis;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
